secwatch.observer — SEC 8-K summary
======================================

Issuer:     GOLDENWELL BIOTECH, INC. (GWLL)
CIK:        0001800373
Form:       8-K
Filed at:   2026-05-27T00:17:04+00:00
Accession:  0001477932-26-003440
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Goldenwell Biotech to restate three quarterly reports over $9,840 legal fee timing errors
--------------------------------------------------------------------------------

- Auditor notified company on May 19, 2025 that legal invoice for $9,840 should have been recorded in service periods (May 2024–Sep 2025), not when received.
- Restatements affect March 31, June 30, and September 30, 2025 Form 10-Qs with additional revenue recognition and prepaid fee classification errors.
- Previously issued financial statements for those quarters should no longer be relied upon regarding the $9,840 legal expense.
- Amendments expected by approximately June 30, 2026; each quarter to recognize $2,280, $2,200, and $2,080 respectively.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800373/000147793226003440/0001477932-26-003440-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800373/000147793226003440/gdwl_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-26-003440

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer